atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from its Phase 2b trial of BPL-003 for treatment-resistant depression.
The randomized, quadruple-masked global study enrolled 193 patients and met its primary and all key secondary endpoints. A single intranasal dose of BPL-003, an intranasal formulation of mebufotenin benzoate, delivered rapid, robust and durable antidepressant effects lasting up to eight weeks.
The treatment was generally well tolerated, with the vast majority of reported adverse events rated as mild or moderate, no drug-related serious adverse events, and no suicide-related safety signals.
The company has selected an 8 mg dose to advance into Phase 3 trials, pending consultation with the US Food and Drug Administration.
Topline data from an eight-week open-label extension stage of the Phase 2b trial is expected in Q3.
The BPL-003 program is being developed through a strategic investment in Beckley Psytech. The planned merger between the two companies is expected to create a combined entity focused on short in-clinic, psychedelic-based mental health therapies, atai said. Shareholder approval is anticipated in the Q4.
Alongside its lead program, atai continues to progress a pipeline that includes VLS-01, a buccal film formulation of DMT for treatment-resistant depression, and EMP-01, an oral R-MDMA candidate for social anxiety disorder, as well as novel 5-HT2A receptor agonists designed to retain potential therapeutic effects without hallucinogenic properties.
“The planned strategic combination with Beckley Psytech is expected to solidify our position as the global leader in the psychedelic mental health space,” atai CEO Dr Srinivas Rao said in a statement.
“By combining our experienced teams and psychedelic expertise as well as adding a late-stage, clinically-validated asset like BPL-003 to our pipeline of wholly owned psychedelic programs, which includes VLS-01 and EMP-01 in Phase 2 clinical development, we are accelerating our ability to bring novel, effective treatments to patients in need.”
Second quarter financial results
atai reported that it exited Q2 with $95.9 million in cash, cash equivalents and short-term securities, compared to $72.3 million at year-end 2024. The increase was driven by proceeds from equity issuances and asset sales, partially offset by operational spending and debt repayments.
With an additional $50 million in committed funding secured in July, the combined company is expected to be financed into the second half of 2027.
atai said that its research and development expenses for the quarter were $11.1 million, a decrease from $12.6 million in the same period last year, reflecting lower personnel and consulting costs.
General and administrative expenses rose to $14.9 million from $13.4 million, primarily due to legal and professional fees related to the planned merger and corporate domicile relocation to the United States.
The company narrowed its net loss to $27.7 million from $57.3 million a year earlier.
“The second quarter marks a pivotal moment for atai and the broader psychedelic sector,” atai co-founder and chairman Christian Angermayer said.
“The continued momentum in scientific validation, regulatory landscape and investor support underscores the growing recognition of psychedelics as a transformative approach to mental health care.”